JP2014518849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518849A5 JP2014518849A5 JP2014506576A JP2014506576A JP2014518849A5 JP 2014518849 A5 JP2014518849 A5 JP 2014518849A5 JP 2014506576 A JP2014506576 A JP 2014506576A JP 2014506576 A JP2014506576 A JP 2014506576A JP 2014518849 A5 JP2014518849 A5 JP 2014518849A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- composition
- amino acid
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 128
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 128
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 128
- 239000000203 mixture Substances 0.000 claims description 80
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 62
- 239000004472 Lysine Substances 0.000 claims description 62
- 241000192125 Firmicutes Species 0.000 claims description 58
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 23
- 241000191967 Staphylococcus aureus Species 0.000 claims description 23
- 241000194017 Streptococcus Species 0.000 claims description 23
- 241000186781 Listeria Species 0.000 claims description 20
- 230000002147 killing effect Effects 0.000 claims description 20
- 241000191940 Staphylococcus Species 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 241000194033 Enterococcus Species 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 108010059993 Vancomycin Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229960003165 vancomycin Drugs 0.000 claims description 8
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 8
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 6
- 241000194032 Enterococcus faecalis Species 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 108010039491 Ricin Proteins 0.000 claims description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 238000011109 contamination Methods 0.000 claims description 6
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 102000002268 Hexosaminidases Human genes 0.000 claims description 4
- 108010000540 Hexosaminidases Proteins 0.000 claims description 4
- 241000186779 Listeria monocytogenes Species 0.000 claims description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 241000191978 Staphylococcus simulans Species 0.000 claims description 4
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 4
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims description 4
- 241000194048 Streptococcus equi Species 0.000 claims description 4
- 241000194026 Streptococcus gordonii Species 0.000 claims description 4
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 4
- 241000194021 Streptococcus suis Species 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229940037648 staphylococcus simulans Drugs 0.000 claims description 4
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 3
- 102000005593 Endopeptidases Human genes 0.000 claims description 2
- 108010059378 Endopeptidases Proteins 0.000 claims description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 34
- 241000186660 Lactobacillus Species 0.000 claims 1
- 101001057111 Staphylococcus aureus Enterotoxin type E Proteins 0.000 claims 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477836P | 2011-04-21 | 2011-04-21 | |
| US61/477,836 | 2011-04-21 | ||
| PCT/US2012/034456 WO2012145630A2 (en) | 2011-04-21 | 2012-04-20 | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095441A Division JP6284976B2 (ja) | 2011-04-21 | 2016-05-11 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518849A JP2014518849A (ja) | 2014-08-07 |
| JP2014518849A5 true JP2014518849A5 (enExample) | 2015-06-11 |
| JP6139509B2 JP6139509B2 (ja) | 2017-05-31 |
Family
ID=47042182
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506576A Expired - Fee Related JP6139509B2 (ja) | 2011-04-21 | 2012-04-20 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2016095441A Active JP6284976B2 (ja) | 2011-04-21 | 2016-05-11 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2017130341A Expired - Fee Related JP6587655B2 (ja) | 2011-04-21 | 2017-07-03 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2018175907A Expired - Fee Related JP6735796B2 (ja) | 2011-04-21 | 2018-09-20 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095441A Active JP6284976B2 (ja) | 2011-04-21 | 2016-05-11 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2017130341A Expired - Fee Related JP6587655B2 (ja) | 2011-04-21 | 2017-07-03 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
| JP2018175907A Expired - Fee Related JP6735796B2 (ja) | 2011-04-21 | 2018-09-20 | グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US9034322B2 (enExample) |
| EP (2) | EP3252155A1 (enExample) |
| JP (4) | JP6139509B2 (enExample) |
| CN (4) | CN103857410A (enExample) |
| AU (3) | AU2012245357B2 (enExample) |
| CA (1) | CA2833409A1 (enExample) |
| DK (1) | DK2699253T3 (enExample) |
| ES (1) | ES2682670T3 (enExample) |
| HK (2) | HK1244503A1 (enExample) |
| IL (4) | IL228869B (enExample) |
| MX (4) | MX383544B (enExample) |
| WO (1) | WO2012145630A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| US20140179594A1 (en) * | 2011-04-21 | 2014-06-26 | The Rockefeller University | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
| NL2007038C2 (en) * | 2011-07-04 | 2013-01-07 | Vereniging Voor Christelijk Hoger Onderwijs | System and method for predicting the viability of a body tissue in a patient, and measuring device used therein. |
| JP6608697B2 (ja) | 2012-05-09 | 2019-11-20 | コントラフェクト コーポレイション | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| RU2646102C2 (ru) | 2012-05-09 | 2018-03-01 | Контрафект Корпорейшн | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
| CN104073478A (zh) * | 2014-06-13 | 2014-10-01 | 上海交通大学 | 杀灭革兰氏阳性菌的酶抗生素及其制备、用途 |
| EP3164146B1 (en) * | 2014-06-26 | 2019-12-25 | The Rockefeller University | Acinetobacter lysins |
| CN104726439B (zh) * | 2015-04-13 | 2017-11-14 | 武汉菲吉乐科生物科技有限公司 | 一种广谱的链球菌裂解酶及其应用 |
| CN104805066B (zh) * | 2015-05-18 | 2018-04-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
| EP3328417A4 (en) * | 2015-07-31 | 2019-02-06 | The Regents of The University of California | MYCOBACTERIUM LYSTERASE: A NEW TREATMENT FOR AKNE |
| EP3341013A4 (en) * | 2015-09-13 | 2018-07-18 | The Rockefeller University | Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION |
| EP3349781A2 (en) | 2015-09-17 | 2018-07-25 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
| DK3454888T3 (da) | 2016-05-12 | 2021-04-26 | Contrafect Corp | Bouillon-mikrofortyndingsfremgangsmåde til evaluering og bestemmelse af minimal inhibitorisk koncentration for antibakterielle polypeptider |
| US20220023399A1 (en) * | 2017-07-10 | 2022-01-27 | Contrafect Corporation | Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof |
| CA3085644A1 (en) | 2017-12-12 | 2019-06-20 | Contrafect Corporation | Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa |
| CN111788299A (zh) * | 2018-01-05 | 2020-10-16 | 阿兹特拉公司 | 葡萄球菌属细菌的营养缺陷型菌株 |
| MX2020008860A (es) * | 2018-02-26 | 2020-12-10 | Contrafect Corp | Lisinas plyss2 modificadas y sus usos. |
| KR102073094B1 (ko) * | 2018-06-04 | 2020-02-04 | (주)인트론바이오테크놀로지 | 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도 |
| KR102073088B1 (ko) * | 2018-06-04 | 2020-02-04 | (주)인트론바이오테크놀로지 | 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도 |
| KR102073086B1 (ko) * | 2018-06-04 | 2020-02-04 | (주)인트론바이오테크놀로지 | 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도 |
| EP3837348A4 (en) * | 2018-08-17 | 2022-07-27 | Becton, Dickinson and Company | TESTING FOR ANTIBIOTIC SENSITIVITY USING MICRODROPLET |
| WO2020077286A1 (en) | 2018-10-12 | 2020-04-16 | Quidel Corporation | Extraction reagent for use in an assay for detection of group a streptococcus |
| CA3134154A1 (en) * | 2019-03-22 | 2020-10-01 | Contrafect Corporation | Method of treating infective endocarditis |
| MX2021012166A (es) * | 2019-04-05 | 2021-11-03 | Contrafect Corp | Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano. |
| JP2022526624A (ja) * | 2019-04-11 | 2022-05-25 | コントラフェクト コーポレイション | 骨及び関節の感染を治療及び予防する方法 |
| IL297953A (en) * | 2020-05-19 | 2023-01-01 | Contrafect Corp | Modified plyss2 lysines and antibiotic combinations for use against gram-positive bacteria |
| US20220087266A1 (en) * | 2020-09-22 | 2022-03-24 | Mars, Incorporated | Compositions and methods for controlling mycotoxin production |
| CN114480299B (zh) * | 2020-10-27 | 2023-08-29 | 暨南大学 | 一种蜡样芽胞杆菌噬菌体及其应用 |
| CA3203004A1 (en) * | 2020-11-25 | 2022-06-02 | Laboratory Corporation Of America Holdings | Methods and systems for the detection of microorganisms using infectious agents |
| CN112760312B (zh) * | 2021-01-20 | 2022-06-17 | 华中农业大学 | 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用 |
| WO2023049747A1 (en) * | 2021-09-22 | 2023-03-30 | Elanco Us Inc. | Streptococcus suis lytic enzyme compositions and methods of use thereof |
| KR102742550B1 (ko) * | 2022-07-26 | 2024-12-18 | 주식회사 인트론바이오테크놀로지 | 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질 |
| WO2024059184A1 (en) * | 2022-09-16 | 2024-03-21 | The Johns Hopkins University | Machine learning systems and related aspects for the detection of disease states |
| CN116640754B (zh) * | 2023-07-21 | 2023-10-10 | 临沂大学 | 一种链球菌前噬菌体裂解酶lys224及应用 |
| CN117965624B (zh) * | 2023-10-11 | 2024-12-17 | 圆因(北京)生物科技有限公司 | 一种用于编码耐甲氧西林金黄色葡萄球菌内溶素的线性dna、线性rna及其质粒表达载体 |
| CN118272361A (zh) * | 2024-05-13 | 2024-07-02 | 内蒙古农业大学 | 一种发酵粘液乳杆菌噬菌体裂解酶LysLFP01及其制备方法和应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278378A (en) | 1962-04-19 | 1966-10-11 | Schindler Charles Alvin | Staphylococcus-derived antibiotic |
| US3398056A (en) | 1964-07-10 | 1968-08-20 | Mead Johnson & Co | Process for producing lysostaphin by fermentation |
| US3594284A (en) | 1968-06-04 | 1971-07-20 | Mead Johnson & Co | Lysostaphin fermentation with accelerated time cycle |
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| AU8108587A (en) | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| US4948580A (en) | 1988-12-08 | 1990-08-14 | E. R. Squibb & Sons, Inc. | Muco-bioadhesive composition |
| JPH02258718A (ja) | 1989-03-31 | 1990-10-19 | Nippon Kayaku Co Ltd | ペースト状基剤及び製剤 |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5554380A (en) | 1994-08-04 | 1996-09-10 | Kv Pharmaceutical Company | Bioadhesive pharmaceutical delivery system |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| US5942243A (en) | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| US6264945B1 (en) | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US5997862A (en) | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
| US20060292135A1 (en) * | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| US6254866B1 (en) | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| HK1047243A1 (zh) | 1999-02-25 | 2003-02-14 | 新眼界诊断公司 | 預防性和治療性治療鏈球菌感染的方法 |
| CN1352567A (zh) * | 1999-02-25 | 2002-06-05 | 新眼界诊断公司 | 预防性和治疗性治疗链球菌感染的方法 |
| US6056955A (en) | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
| AU2003291614A1 (en) | 2002-05-17 | 2004-04-08 | New Horizons Diagnostics Corporation | Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| US8326388B2 (en) | 2002-10-31 | 2012-12-04 | Toshiba Medical Systems Corporation | Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics |
| US7217791B2 (en) * | 2002-11-07 | 2007-05-15 | Synergy America, Inc. | Compositions and methods for treating or preventing pneumococcal infection |
| US7582729B2 (en) * | 2003-05-15 | 2009-09-01 | The Rockefeller University | Nucleic acids and polypeptides of C1 bacteriophage and uses thereof |
| US7569223B2 (en) | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| EP1744779A2 (en) | 2004-03-24 | 2007-01-24 | The Rockfeller University | Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores |
| GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
| US7582291B2 (en) * | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
| EP2360248A1 (en) | 2005-08-24 | 2011-08-24 | The Rockefeller University | Ply-GBS mutant lysins |
| IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
| DE102006061002A1 (de) * | 2006-12-22 | 2008-06-26 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien |
| CA2706600A1 (en) * | 2007-11-26 | 2009-06-04 | Plant Bioscience Limited | Novel polypeptides having endolysin activity and uses thereof |
| EP2103308A1 (de) * | 2008-03-20 | 2009-09-23 | PhytoLine GmbH | Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen |
| CA2729160C (en) | 2008-07-03 | 2017-11-14 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| US8481289B2 (en) * | 2008-07-24 | 2013-07-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Triple acting antimicrobials that are refractory to resistance development |
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| KR101016918B1 (ko) * | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| CN103080307A (zh) * | 2010-01-25 | 2013-05-01 | 美艾利尔斯卡保罗有限公司 | A25噬菌体溶解酶 |
| US20140179594A1 (en) * | 2011-04-21 | 2014-06-26 | The Rockefeller University | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
-
2012
- 2012-04-20 CA CA2833409A patent/CA2833409A1/en active Pending
- 2012-04-20 JP JP2014506576A patent/JP6139509B2/ja not_active Expired - Fee Related
- 2012-04-20 MX MX2019015029A patent/MX383544B/es unknown
- 2012-04-20 WO PCT/US2012/034456 patent/WO2012145630A2/en not_active Ceased
- 2012-04-20 EP EP17181258.9A patent/EP3252155A1/en not_active Withdrawn
- 2012-04-20 US US14/112,963 patent/US9034322B2/en active Active
- 2012-04-20 AU AU2012245357A patent/AU2012245357B2/en not_active Ceased
- 2012-04-20 CN CN201280027294.6A patent/CN103857410A/zh active Pending
- 2012-04-20 MX MX2016000588A patent/MX370442B/es unknown
- 2012-04-20 ES ES12773653.6T patent/ES2682670T3/es active Active
- 2012-04-20 DK DK12773653.6T patent/DK2699253T3/en active
- 2012-04-20 CN CN201810396150.7A patent/CN108578685A/zh active Pending
- 2012-04-20 CN CN202211173250.6A patent/CN115887627A/zh active Pending
- 2012-04-20 EP EP12773653.6A patent/EP2699253B1/en active Active
- 2012-04-20 MX MX2013012241A patent/MX336427B/es unknown
- 2012-04-20 CN CN201710504268.2A patent/CN107189997A/zh active Pending
-
2013
- 2013-10-14 IL IL228869A patent/IL228869B/en active IP Right Grant
- 2013-10-18 MX MX2021007008A patent/MX2021007008A/es unknown
-
2015
- 2015-04-14 US US14/685,696 patent/US9914915B2/en active Active
-
2016
- 2016-05-11 JP JP2016095441A patent/JP6284976B2/ja active Active
-
2017
- 2017-04-20 US US15/492,128 patent/US10544407B2/en active Active
- 2017-04-26 AU AU2017202728A patent/AU2017202728B2/en not_active Ceased
- 2017-07-03 JP JP2017130341A patent/JP6587655B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-20 HK HK18103869.2A patent/HK1244503A1/zh unknown
- 2018-06-01 HK HK18107229.8A patent/HK1247956A1/en unknown
- 2018-09-20 JP JP2018175907A patent/JP6735796B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-06 IL IL266476A patent/IL266476B/en active IP Right Grant
- 2019-06-28 AU AU2019204660A patent/AU2019204660B2/en not_active Ceased
- 2019-09-05 US US16/561,130 patent/US11155799B2/en active Active
- 2019-12-09 US US16/707,733 patent/US11111484B2/en active Active
- 2019-12-10 IL IL271300A patent/IL271300B/en unknown
-
2021
- 2021-09-03 US US17/465,931 patent/US20230167427A9/en not_active Abandoned
- 2021-09-15 US US17/476,030 patent/US20220064615A1/en not_active Abandoned
- 2021-10-24 IL IL287530A patent/IL287530A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518849A5 (enExample) | ||
| Tagg | Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius | |
| E. Greber et al. | Antimicrobial peptides under clinical trials | |
| Nuti et al. | Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance | |
| Howard et al. | Acinetobacter baumannii: an emerging opportunistic pathogen | |
| KR102419616B1 (ko) | 항균 요법 | |
| Wang et al. | A phage lysin fused to a cell-penetrating peptide kills intracellular methicillin-resistant Staphylococcus aureus in keratinocytes and has potential as a treatment for skin infections in mice | |
| CA2981996C (en) | Broad spectrum of streptococcus lyase and use thereof | |
| EP3349781A2 (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
| Simoes et al. | Novel antibacterial agents: an emergent need to win the battle against infections | |
| Ashby et al. | Cationic antimicrobial peptides as potential new therapeutic agents in neonates and children: a review | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| Wladyka et al. | Isolation, biochemical characterization, and cloning of a bacteriocin from the poultry-associated Staphylococcus aureus strain CH-91 | |
| RU2017106290A (ru) | Бактериофаги, фаговые пептиды и способы их применения | |
| Ciandrini et al. | Antimicrobial activity of different antimicrobial peptides (AMPs) against clinical methicillin-resistant Staphylococcus aureus (MRSA) | |
| JPH11508265A (ja) | 抗生物質抵抗性グラム陽性細菌の制御および感染治療の方法 | |
| JP2013523718A5 (enExample) | ||
| US20150087579A1 (en) | Antimicrobial peptides | |
| CN112867398A (zh) | 溶素及其衍生物使金黄色葡萄球菌和革兰氏阳性菌对抗生素重新敏感 | |
| CN107177580B (zh) | 一种广谱新型嵌合裂解酶GBS-PlySb及其编码基因和应用 | |
| CN112501189A (zh) | 一种能杀死马链球菌马亚种的裂解酶及其医用用途 | |
| Rahimzadeh et al. | Endolysins of bacteriophages as an anti-methicillin resistant staphylococcus aureus infection in children: a narrative review | |
| WO2008105826A2 (en) | Compositions compromising lysostaphin variants and methods of using the same | |
| JP2015515280A5 (enExample) | ||
| Ceotto et al. | Nukacin 3299, a lantibiotic produced by Staphylococcus simulans 3299 identical to nukacin ISK-1 |